Good looking results for Novo Nordisk's combo of GLP1ra semaglutide (known as #ozempic for #diabetes & #wegovy for obesity) + Cagrilintide (amylin agonist) to achieve #weightloss in obesity and obesity with type Novo Nordisk Advances Cagrilintide to Phase 3 Clinical Program After Positive Results CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Hypertension PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta Analysis Journal of Clinical Question Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine